复发或难治性外周T细胞淋巴瘤的新型药物和治疗方案：2023年美国血液学会年会的最新进展
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting.
作者信息
Huang Huageng, Zhang Wei, Deng Xinyi, Huang He, Wang Zhao, Hong Huangming, Lin Tongyu
机构信息
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Department of Medical Oncology, Senior Ward and Phase I Clinical Trial Ward, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, 610000, Sichuan, China.
出版信息
Exp Hematol Oncol. 2024 Apr 22;13(1):44. doi: 10.1186/s40164-024-00510-w.
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of hematological malignancies with poor survival, while treatment options for relapsed or refractory (R/R) disease remain quite limited, with a median progression-free survival of only 3-4 months. Notably, the emergence of innovative therapeutic agents and regimens holds promise for durable responses and improved survival for patients with R/R PTCL. We summarize recent advances in the treatment of R/R PTCL from the 2023 ASH Annual Meeting, highlighting novel agents targeting EZH1/2, JAK1, PI3K, KIR3DL2, CD38/CD3xCD28, or CDK9, as well as therapeutic regimens in combination with stem cell transplantation, immunomodulators, epigenetic modifying agents, or CD30/CD16A bispecific antibodies.
外周T细胞淋巴瘤（PTCL）是一组异质性血液系统恶性肿瘤，生存率较低，而复发性或难治性（R/R）疾病的治疗选择仍然非常有限，无进展生存期的中位数仅为3至4个月。值得注意的是，创新治疗药物和方案的出现为R/R PTCL患者带来了持久缓解和生存改善的希望。我们总结了2023年美国血液学会年会（ASH）上R/R PTCL治疗的最新进展，重点介绍了靶向EZH1/2、JAK1、PI3K、KIR3DL2、CD38/CD3xCD28或CDK9的新型药物，以及与干细胞移植、免疫调节剂、表观遗传修饰剂或CD30/CD16A双特异性抗体联合的治疗方案。
Zotero 插件